This observational study, sponsored by Changhai Hospital, aims to elucidate the risk factors influencing glycemic status and treatment optimization in patients with post-chronic pancreatitis diabetes mellitus (PPDM-C). With an enrollment of 324 patients, the study is positioned to provide valuable insights into the management of diabetes following chronic pancreatitis, a niche yet significant area within the diabetes market. The findings could enhance treatment protocols and potentially lead to the development of targeted therapies or diagnostic tools. Given the increasing prevalence of diabetes and the complexities associated with its management post-pancreatitis, the study may attract interest from pharmaceutical companies focusing on diabetes care and chronic disease management. However, the competitive landscape includes established diabetes treatments and emerging therapies targeting specific patient populations.